Ihe ọmụma
Onivyde ntụ ntụ bụ ụdị pụrụ iche nke irinotecan, ọgwụ chemotherapy nke a na-ejikarị na-agwọ ọrịa cancer metastatic. Emebere usoro ihe ọhụrụ a iji kwalite nrụpụta yana belata mmetụta ndị metụtara ọgwụgwọ irinotecan ọdịnala. Onivyde, nke a makwaara dị ka liposomal irinotecan, na-ekpuchi ọgwụ na-arụ ọrụ na obere irighiri lipid, na-enye ohere maka ntọhapụ ezubere iche na ogologo oge n'ime ahụ.
Kedu ka Onivyde Powder si dị iche na irinotecan omenala?
Onivyde ntụ ntụ na-anọchi anya ọganihu dị ịrịba ama na ọgwụgwọ ọrịa kansa, karịsịa n'otú o si dị iche na irinotecan omenala. Isi ihe dị iche bụ n'ụdị liposomal ọhụrụ ya. N'adịghị ka irinotecan nkịtị, nke na-ekesa kpam kpam n'ime ọbara, Onivyde na-etinye ọgwụ ahụ n'ime obere irighiri lipid. Ihe mkpuchi a na-eje ozi dị iche iche, nke ọ bụla na-enye aka n'ịkwalite nrụpụta ya yana mma nnabata.
Nke mbụ, usoro liposomal nke Onivyde na-enye ohere maka nnyefe ezubere iche nke ọgwụ ahụ na mkpụrụ ndụ kansa. Emebere irighiri ihe na-egbu egbu ka ọ na-agbakọ nke ọma na anụ ahụ tumor, na-eji ohere nkwalite na njigide (EPR) emelitere na-ahụkarị na etuto siri ike. Usoro a ezubere iche pụtara na ntinye ọgwụ dị elu na-erute ebe a na-eme atụmatụ, nwere ike ịbawanye irè ya megide mkpụrụ ndụ kansa.
Nke abuo, usoro liposomal na-agbanwe pharmacokinetics nke irinotecan. A na-ekpochapụ irinotecan omenala ngwa ngwa n'ahụ, na-achọ ka a na-eme ya ugboro ugboro ma nwee ike iduga n'ọkwa ọgwụ na-agbanwe agbanwe. N'ụzọ dị iche, nhazi liposomal Onivyde na-arụ ọrụ dị ka ebe nchekwa, na-eji nwayọọ nwayọọ na-ahapụ ọgwụ ahụ na-arụ ọrụ ruo ogologo oge. Profaịlụ ntọhapụ a na-adịgide adịgide na-edobe ọkwa ọgwụgwọ ọgwụgwọ ruo ogologo oge, nwere ike ịkwalite ikike ọgwụ ahụ ịlụso mkpụrụ ndụ kansa ọgụ mgbe niile.
Pharmacokinetics nke Onivyde emezigharịrị na-atụnyekwa aka na profaịlụ akụkụ mmetụta ya ka mma. Site n'ibelata mkpokọta plasma kacha elu yana inye ntọhapụ nke nta nke nta karị, Onivyde nwere ike inye aka belata ụfọdụ mmetụta ọjọọ ndị metụtara irinotecan ọdịnala, dị ka afọ ọsịsa siri ike na neutropenia. Nkwekọrịta a ka mma nwere ike ịdị mkpa maka ndị ọrịa, nwere ike inye ohere ogologo oge ọgwụgwọ yana ndụ ka mma n'oge ọgwụgwọ.
Ọzọkwa, ụdị liposomal nke Onivyde nwere ike inye aka imeri usoro mgbochi ụfọdụ mkpụrụ ndụ kansa na-etolite megide irinotecan ọdịnala. Mgbanwe nke mkpụrụ ndụ cellular na nhazi intracellular nke ọgwụ liposomal nwere ike ịgafe ụfọdụ nfuli mgbapụta na ụzọ nkwụsị nke enzymatic nke mkpụrụ ndụ tumo na-eji eguzogide ụdị irinotecan.
Ọ dị mkpa ịmara na ọ bụ ezie na Onivyde na-enye uru ndị a, ọ bụghị onye na-anọchi anya ihe niile eji eme ụdị irinotecan. Ngosipụta akwadoro ya bụ nke akọwapụtara nke ọma, na-elekwasị anya na ọrịa cancer pancreatic metastatic yana yana ndị ọzọ na-ahụ maka chemotherapy. Nhọrọ n'etiti Onivyde na irinotecan omenala dabere n'ihe dị iche iche, gụnyere ụdị na ogbo nke ọrịa kansa, ọgwụgwọ ndị gara aga, na njirimara onye ọrịa.
Kedu ka Onivyde Powder si dị irè n'ịgwọ ọrịa kansa pancreatic?
Ịdị irè nke Onivyde ntụ ntụ N'ịgwọ ọrịa cancer pancreatic, karịsịa ọrịa cancer pancreatic metastatic, abụrụla isiokwu nke nchọpụta ụlọ ọgwụ dị ịrịba ama. Achọpụtara ịdị irè ya nke ọma n'ihe gbasara iji ya akwadoro: dịka ọgwụgwọ nke abụọ maka ọrịa cancer pancreatic metastatic na ndị ọrịa ejirila ọgwụgwọ dabere na gemcitabine na mbụ.
Nnwale NAPOLI-1 dị mkpa, nke mere ka FDA kwadoro Onivyde, gosipụtara ọganihu dị ịrịba ama na ndụ zuru oke na ndụ na-enweghị ọganihu mgbe ejiri Onivyde na 5-fluorouracil na leucovorin. Ọmụmụ ihe ọmụmụ nke atọ a gosiri na ndị ọrịa na-emeso ya na Onivyde nchikota nwere ogologo ndụ nke ọnwa 6.1, ma e jiri ya tụnyere ọnwa 4.2 maka ndị na-anata 5-fluorouracil na leucovorin naanị. Ọ bụ ezie na ọnụọgụ ndị a nwere ike iyi obere ihe, ha na-anọchite anya mmụba dị ịrịba ama na ụdị ọrịa cancer nke akụkọ ihe mere eme arụpụtaghị ihe na-adịghị mma.
Ọzọkwa, nnyocha ahụ chọpụtara na ihe dị ka 16% nke ndị ọrịa a na-emeso ya na nchikota Onivyde dị ndụ otu afọ ma ọ bụ karịa, ma e jiri ya tụnyere 6% na otu njikwa. Mmụba nke ọnụ ọgụgụ nlanarị nke otu afọ a bụ ihe dị ịrịba ama karịsịa n'ihe gbasara ọrịa kansa pancreatic metastatic, ebe ndụ ogologo oge adịghị ụkọ.
Atụle ịdị irè nke Onivyde abụghị naanị na ọnụ ọgụgụ nlanarị. Ogo ndụ yana ọnụego nzaghachi tumor bụkwa ihe dị mkpa. Nnwale NAPOLI-1 kwuru na 7.7% nke ndị ọrịa nọ na otu Onivyde na-emekọ ihe na-enweta nzaghachi nke ọma na ọgwụgwọ, ma e jiri ya tụnyere 0.8% n'ime otu njikwa. Nke a na-egosi na Onivyde nwere ike inye aka belata etuto ahụ na ụfọdụ ndị ọrịa, nwere ike ibelata mgbaàmà yana ime ka ndụ dịkwuo mma.
Ọ dị mkpa ịmara na arụmọrụ Onivyde nwere ike ịdịgasị iche n'etiti ndị mmadụ n'otu n'otu. Ihe ndị dị ka ahụike n'ozuzu onye ọrịa, oke ọrịa metastatic, na ọgwụgwọ ndị gara aga nwere ike imetụta otú onye ọrịa si anabata ọgwụgwọ Onivyde. Na mgbakwunye, ọmụmụ biomarker na-aga n'ihu iji chọpụta ọnụ ọgụgụ ndị ọrịa nwere ike nweta uru kachasị na ọgwụgwọ Onivyde.
Ọ bụ ezie na Onivyde gosipụtara nkwa na usoro ọgwụgwọ nke abụọ nke ọrịa cancer pancreatic metastatic, nyocha na-aga n'ihu iji chọpụta ikike ya na ntọala ndị ọzọ. Nnyocha na-enyocha iji ya na ọgwụgwọ nke mbụ, yana ọgwụ ndị ọzọ na-agwọ ọrịa, na ụdị ọrịa cancer dị iche iche. Nnyocha ndị a na-aga n'ihu nwere ike ịkọwapụta ikike Onivyde nwere na ọgwụgwọ ọrịa kansa.
Ọ dị mkpa ịghọta na ọ bụ ezie na Onivyde na-anọchite anya ọganihu dị mkpa na ọgwụgwọ ọrịa cancer pancreatic metastatic, ọ bụghị ọgwụgwọ. Ọrịa cancer pancreatic, ọkachasị n'oge metastatic ya, ka bụ ọrịa siri ike ịgwọ. Onivyde bụ akụkụ nke usoro ọgwụgwọ sara mbara nke nwere ike ịgụnye ọgwụ chemotherapy ndị ọzọ, usoro ọgwụgwọ ezubere iche, na usoro nlekọta nkwado.
Ekwesịrị ịtụle ịdị irè nke Onivyde n'ihe gbasara profaịlụ mmetụta ya. Ọ bụ ezie na a na-anabata ya nke ọma karịa irinotecan ọdịnala, Onivyde ka nwere ike ịkpata mmetụta dị egwu nke nwere ike imetụta ụdị ndụ onye ọrịa. Ntụle n'etiti ịdị irè na ndidi bụ ihe dị mkpa na mkpebi ọgwụgwọ.
Kedu ihe mmetụta Onivyde Powder nwere?
mgbe Onivyde ntụ ntụ na-anọchi anya ọganihu na ọgwụgwọ ọrịa kansa site na nhazi liposomal nke irinotecan, ọ dị mkpa ịghọta na, dịka ọgwụ ọgwụ chemotherapy niile, ọ nwere ike ịkpata mmetụta. Profaịlụ mmetụta mmetụta nke Onivyde, ebe ọ na-akawanye mma ma e jiri ya tụnyere irinotecan ọdịnala, ka na-achọ nleba anya na njikwa nke ọma.
Ọgbụgbọ na ọgbụgbọ bụ mmetụta na-emetụtakarị na ọgwụgwọ Onivyde. Mgbaàmà ndị a nwere ike ịdị n'ụdị dị nro ruo nke siri ike ma nwee ike imetụta agụụ na ụdị ndụ onye ọrịa. A na-enyekarị ọgwụ antiemetic na prophylactic iji nyere aka ịchịkwa mgbaàmà ndị a.
Ike ọgwụgwụ bụ mmetụta ọzọ a na-akọkarị. Nke a nwere ike ịmalite site na ike ọgwụgwụ dị nro ruo oke ike ọgwụgwụ nke na-egbochi ihe omume kwa ụbọchị. Ike ọgwụgwụ na-ejikọta na ọgwụgwọ Onivyde na-abụkarị mkpokọta, nke pụtara na ọ nwere ike ịka njọ n'oge ọgwụgwọ.
Nlekọta nke mmetụta dị n'akụkụ bụ akụkụ dị oke mkpa nke ọgwụgwọ Onivyde. Ndị na-ahụ maka ahụike na-ejikarị usoro mkpachapụ anya, nke nwere ike ịgụnye:
1. Ọgwụ mgbochi iji gbochie ma ọ bụ belata oke mmetụta nke mmetụta.
2. Nleba anya mgbe niile site na nyocha ọbara na nyocha anụ ahụ.
3. Mgbanwe dose ma ọ bụ ọgwụgwọ na-egbu oge ma ọ bụrụ na mmetụta dị njọ na-eme.
4. Nkuzi onye ọrịa na-amata na ịkọ akụkọ mmetụta ozugbo.
5. Usoro nlekọta nkwado, dị ka njikwa hydration na nkwado nri.
Ọ dị mkpa maka ndị ọrịa na-anata Onivyde ka ha na ndị otu ahụike ha na-ekwurịta okwu maka mmetụta ọ bụla ha nwetara. Nghọta mbụ na njikwa nke mmetụta ndị nwere ike imeziwanye nsonaazụ ọgwụgwọ na ịdị mma ndụ n'oge ọgwụgwọ.
Na ngwụcha, Onivyde ntụ ntụ egosila mmụba bara uru na nlanarị yana ọnụego nzaghachi maka ndị ọrịa nwere ọrịa kansa pancreatic metastatic bụ ndị nwere ọganihu na ọgwụgwọ dabere na gemcitabine tupu oge eruo. Usoro nke liposomal ya na-enye ụzọ ọhụrụ iji nyefee irinotecan, nwere ike ịkwalite nrụpụta ya ma na-ebelata ụfọdụ nsí ya. Ka nyocha na-aga n'ihu, nghọta anyị banyere otu esi eji Onivyde na ọgwụgwọ ọrịa cancer nke ọma nwere ike ịmalite, nwere ike gbasaa ọrụ ya na ọrịa cancer pancreatic yana ikekwe ọrịa ndị ọzọ.
Ọ bụrụ na ị nwekwara mmasị na ngwaahịa a ma chọọ ịmatakwu nkọwa ngwaahịa, ma ọ bụ chọọ ịmata maka ngwaahịa ndị ọzọ metụtara, biko nweere onwe gị ịkpọtụrụ. iceyqiang@aliyun.com.
References:
1. Wang-Gillam, A., et al. (2016). Nanoliposomal irinotecan na fluorouracil na folinic acid na metastatic pancreatic cancer mgbe gara aga gemcitabine dabeere na ọgwụgwọ (NAPOLI-1): a zuru ụwa ọnụ, randomised, na-emeghe-label, 3 nkeji ikpe. The Lancet, 387 (10018), 545-557.
2. Drummond, DC, et al. (2006). Mmepe nke nanoliposomal irinotecan na-arụsi ọrụ ike nke ukwuu na-eji atụmatụ intraliposomal stabilization ọhụrụ. Nnyocha Ọrịa Cancer, 66 (6), 3271-3277.
3. Nwa atụrụ, YN, & Scott, LJ (2017). Liposomal Irinotecan: Nyochaa na Metastatic Pancreatic Adenocarcinoma. Ọgwụ ọjọọ, 77 (7), 785-792.
4. Ko, AH (2016). Nanomedicine na etuto dị iche iche: na-ezubere ndị siri ike ịgwọ. Akwụkwọ akụkọ nke National Cancer Institute, 108(9), djw159.
5. Kalra, AV, et al. (2014). A na-achịkwa ọrụ izizi nke nanoliposomal irinotecan site na ntinye akpụ na ntughari prodrug intratumor. Nnyocha Ọrịa Cancer, 74 (23), 7003-7013.
6. Kipps, E., et al. (2017). Ịghọta na ijikwa toxicities nke vascular endothelial growth factor (VEGF) inhibitors. Akwụkwọ akụkọ European nke Ọrịa Cancer, 84, 213-221.
7. Saif, MW (2014). MM-398 nwetara isi njedebe nke ndụ zuru oke na ọmụmụ nke III na ndị ọrịa nwere ọrịa cancer pancreatic gemcitabine refractory metastatic. JOP: Akwụkwọ akụkọ nke Pancreas, 15 (3), 278-279.
8. Rahma, OE, et al. (2013). Ọgwụgwọ nke abụọ na ọrịa kansa pancreatic dị elu: nyocha zuru oke nke nnwale ụlọ ọgwụ ebipụtara. Akụkọ banyere Oncology, 24 (8), 1972-1979.
9. Von Hoff, DD, et al. (2013). Mmụba ndụ na ọrịa kansa pancreatic na nab-paclitaxel gbakwunyere gemcitabine. Akwụkwọ akụkọ ọgwụ New England, 369 (18), 1691-1703.
10. Ducreux, M., et al. (2015). Ọrịa cancer nke pancreas: ESMO Clinical Practice Guidelines maka nchoputa, ọgwụgwọ na nsonye. Akwụkwọ akụkọ nke Oncology, 26 (suppl_5), v56-v68.
